| Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia H Kantarjian, C Sawyers, A Hochhaus, F Guilhot, C Schiffer, ... New England Journal of Medicine 346 (9), 645-652, 2002 | 2708 | 2002 |
| Clinical and biological implications of driver mutations in myelodysplastic syndromes E Papaemmanuil, M Gerstung, L Malcovati, S Tauro, G Gundem, ... Blood, The Journal of the American Society of Hematology 122 (22), 3616-3627, 2013 | 2061 | 2013 |
| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 1852* | 2020 |
| Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study: Presented in part at … CL Sawyers, A Hochhaus, E Feldman, JM Goldman, CB Miller, ... Blood, The Journal of the American Society of Hematology 99 (10), 3530-3539, 2002 | 1533 | 2002 |
| Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study M Talpaz, RT Silver, BJ Druker, JM Goldman, C Gambacorti-Passerini, ... Blood, The Journal of the American Society of Hematology 99 (6), 1928-1937, 2002 | 1471 | 2002 |
| Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts E Papaemmanuil, M Cazzola, J Boultwood, L Malcovati, P Vyas, D Bowen, ... New England Journal of Medicine 365 (15), 1384-1395, 2011 | 1458 | 2011 |
| A phase 2 trial of ponatinib in Philadelphia chromosome–positive leukemias JE Cortes, DW Kim, J Pinilla-Ibarz, P Le Coutre, R Paquette, C Chuah, ... New England Journal of Medicine 369 (19), 1783-1796, 2013 | 1288 | 2013 |
| Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells V Zuco, R Supino, SC Righetti, L Cleris, E Marchesi, ... Cancer letters 175 (1), 17-25, 2002 | 739 | 2002 |
| Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification P le Coutre, E Tassi, M Varella-Garcia, R Barni, L Mologni, G Cabrita, ... Blood, The Journal of the American Society of Hematology 95 (5), 1758-1766, 2000 | 706 | 2000 |
| Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial JE Cortes, DW Kim, HM Kantarjian, TH Brümmendorf, I Dyagil, ... Journal of Clinical Oncology 30 (28), 3486-3492, 2012 | 577 | 2012 |
| Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study F Passamonti, C Cattaneo, L Arcaini, R Bruna, M Cavo, F Merli, ... The Lancet Haematology 7 (10), e737-e745, 2020 | 570 | 2020 |
| Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial JE Cortes, DW Kim, J Pinilla-Ibarz, PD le Coutre, R Paquette, C Chuah, ... Blood, The Journal of the American Society of Hematology 132 (4), 393-404, 2018 | 555 | 2018 |
| Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib JE Cortes, HM Kantarjian, TH Brümmendorf, DW Kim, AG Turkina, ... Blood, The Journal of the American Society of Hematology 118 (17), 4567-4576, 2011 | 548 | 2011 |
| Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib C Gambacorti-Passerini, L Antolini, FX Mahon, F Guilhot, M Deininger, ... Journal of the National Cancer Institute 103 (7), 553-561, 2011 | 537 | 2011 |
| Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. S Redaelli, R Piazza, R Rostagno, V Magistroni, P Perini, M Marega, ... Journal of clinical oncology: official journal of the American Society of …, 2008 | 520 | 2008 |
| Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias CB Gambacorti-Passerini, RH Gunby, R Piazza, A Galietta, R Rostagno, ... The lancet oncology 4 (2), 75-85, 2003 | 517 | 2003 |
| Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial JE Cortes, C Gambacorti-Passerini, MW Deininger, MJ Mauro, C Chuah, ... Journal of Clinical Oncology 36 (3), 231-237, 2018 | 513 | 2018 |
| In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor P Le Coutre, L Mologni, L Cleris, E Marchesi, E Buchdunger, R Giardini, ... Journal of the National Cancer Institute 91 (2), 163-168, 1999 | 495 | 1999 |
| Role of α1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571 C Gambacorti-Passerini, R Barni, P le Coutre, M Zucchetti, G Cabrita, ... Journal of the National Cancer Institute 92 (20), 1641-1650, 2000 | 491 | 2000 |
| In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells M Puttini, AML Coluccia, F Boschelli, L Cleris, E Marchesi, ... Cancer research 66 (23), 11314-11322, 2006 | 483 | 2006 |
